2592 — Cloudbreak Pharma Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeSmall Cap
- HK$1.10bn
- HK$799.51m
Hong Kong watchdog tells firms how to cooperate in raids as scrutiny of share sales grows
Brief: Cloudbreak Pharma Says FDA Completes Safety Review Of CBT-358 Ind Application With No Objection
Brief: Cloudbreak Pharma Enters Share Subscription Agreement With Arc Group International For Up To $15 Mln
Brief: Cloudbreak Pharma Announces Final Patient Visit for 12-Month Efficacy Endpoint in Phase 3 Study of CBT-001 as a Potential Treatment for Pterygium
Brief: Cloudbreak Pharma Submits IND Application For Cbt-358 To FDA
Brief: Cloudbreak Pharma Says FDA Completes Safety Review Of CBT-199 IND Application; Clinical Investigation May Proceed
Brief: Cloudbreak Pharma Redeems Fund In Full, Receives Hk$48.0 Million, Records HK$0.88 Million Gain
Brief: Cloudbreak Pharma Withdraws IND Application For CBT-009 Phase 3 Trial In China
Brief: Cloudbreak Pharma Inc Says Withdrawal Of Arbitration Proceedings On 28 Jan
Brief: Cloudbreak Pharma Inc Announces Settlement Of Legal Proceedings
Brief: Cloudbreak Pharma Inc Says Unit Receives Court Notice Dated 24 December
Brief: Cloudbreak Pharma Says Unit Submitted IND Application For CBT-009 To NMPA
Brief: Cloudbreak Pharma Says ADS Therapeutics Submits IND Application To FDA For CBT-199
Cloudbreak gains on new drug's progress
Cloudbreak jumps on successful patent applications in Japan, Europe
Brief: Cloudbreak Pharma Expects HY Net Profit Before Income Tax Of At Least $4.5 Million